Use of Low-level Laser Therapy in the Treatment of Diabetic Foot Ulcers

Sponsor
Federal University of Piaui (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT04246814
Collaborator
(none)
80
1
4
39.7
2

Study Details

Study Description

Brief Summary

Diabetes mellitus (DM) is currently an important cause of morbidity and mortality. Global estimates indicate that 382 million people live with diabetes (8.3%), and that number could reach 592 million in 2035. The diabetic foot ulcers (DFU) present as sore wounds with disintegration of the skin. The DFU affect 15% of diabetic patients. Several studies have been conducted aiming to find therapeutic strategies for the healing of DFU, among the reported therapeutic methods the Low-level Laser Therapy (LLLT) has been highlighted. The aim of this study is to investigate the effects of different doses of LLLT in the treatment of DFU. Methods: This study is characterized as a double-blind randomized clinical trial (RCT), consisting of four groups, the control group will have only dressing and placebo LLLT application and the other three groups will have dressing and real LLLT GaAs 904 nm application. Expected outcomes: to elucidate the effects of different doses of LLLT GaAs 904 nm on the treatment of DFU, beyond to identify the most effective dose.

Condition or Disease Intervention/Treatment Phase
  • Device: LG1
  • Device: LG2
  • Device: LG3
  • Device: CC
  • Procedure: Dressing
Phase 2

Detailed Description

All groups will perform the same procedures twice weekly. Volunteers will be comfortable with the affected foot exposed. The diabetic foot ulcers (DFU) will be cleaned using saline solution and gauze, then the ulcer temperature will be checked using the digital infrared thermometer. Diabetic wounds will be measured and photographed at baseline and every 10 visits until the study is completed, the images will be analyzed using the ImageJ program for follow-up throughout the intervention. The DFU will be ranked according to the Wagner Scale. Afterwards the volunteers will receive LLLT application and conventional treatment in the form of Helianthus Annuus oil dressing. Both therapist and participant will be instructed on precautions to be observed when using LLLT. Goggles will be provided prior to administration. The lower cylinder of the LASER probe will be placed perpendicular to the DFU, the floor and edges of the ulcer will be irradiated using punctual and scanning techniques, respectively. Once a week blood glucose levels will be obtained for patient screening. All data will be recorded until the end of the visits in a control form prepared.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
80 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Masking Description:
Masking will be double-blind, the volunteer and outcome assessor will not be aware of the individual allocation of participants in the intervention groups.
Primary Purpose:
Treatment
Official Title:
Effect of Low-level Laser Therapy in the Treatment of Diabetic Foot Ulcers: a Double-blind Randomized Controlled Trial
Actual Study Start Date :
Aug 27, 2019
Actual Primary Completion Date :
Aug 18, 2021
Anticipated Study Completion Date :
Dec 18, 2022

Arms and Interventions

Arm Intervention/Treatment
Placebo Comparator: CC + dressing

The group will receive placebo LASER application associated with Helianthus annuus oil dressing.

Device: CC
Application of placebo LASER.

Procedure: Dressing
Application of Helianthus annuus oil dressing.

Active Comparator: LG1 + dressing

The group will receive application of LASER Gallium Arsenide (GaAs) 904 nm 10 J/cm² associated with Helianthus annuus oil dressing.

Device: LG1
Application of LASER AsGa 904nm 10 J/cm².

Procedure: Dressing
Application of Helianthus annuus oil dressing.

Active Comparator: LG2 + dressing

The group will receive application of LASER Gallium Arsenide (GaAs) 904 nm 8 J/cm² associated with Helianthus annuus oil dressing.

Device: LG2
Application of LASER AsGa 904nm 8 J/cm².

Procedure: Dressing
Application of Helianthus annuus oil dressing.

Active Comparator: LG3 + dressing

The group will receive application of LASER Gallium Arsenide (GaAs) 904 nm 4 J/cm² associated with Helianthus annuus oil dressing.

Device: LG3
Application of LASER AsGa 904nm 4 J/cm².

Procedure: Dressing
Application of Helianthus annuus oil dressing.

Outcome Measures

Primary Outcome Measures

  1. Change in the ulcer area [Before intervention starts, 5th and 10th week of intervention.]

    Measure of ulcer area change.

  2. Change in complete ulcer healing [Before intervention starts, 5th and 10th week of intervention.]

    Change in the percentage of complete ulcer healing.

Secondary Outcome Measures

  1. Wagner Classification [Before intervention starts, 5th and 10th week of intervention and after 1 month and after 1 month.]

    Ulcer categorization according to Wagner Classification.

  2. Blood glucose [Before intervention starts, 5th and 10th week of intervention and after 1 month and after 1 month.]

    Glycemic levels.

  3. Temperature [Before intervention starts, 5th and 10th week of intervention.]

    Ulcer temperature.

  4. Short Form-36 Health Survey questionnaire [Before intervention starts, 5th and 10th week of intervention and after 1 month and after 1 month.]

    The Short Form-36 Health Survey questionnaire (SF 36) assesses quality of life and consists of 36 questions, covering 8 domains. This questionnaire has a final score from 0 to 100, in which zero corresponds to the worst general health status and 100 to the best health status.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 79 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Type 2 diabetes mellitus patients with diabetic foot ulcers;

  • Patients aged 18 and over.

Exclusion Criteria:
  • Type 2 diabetes mellitus patients with ulcers in parts of the body other than the feet;

  • Patients with infected diabetic foot ulcers.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Federal University of Piaui Parnaíba Piauí Brazil 64202-020

Sponsors and Collaborators

  • Federal University of Piaui

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Vinicius Saura Cardoso, PhD Professor of the Graduate Program in Biomedical Sciences, Federal University of Piaui
ClinicalTrials.gov Identifier:
NCT04246814
Other Study ID Numbers:
  • 17081119.1.0000.5214
First Posted:
Jan 29, 2020
Last Update Posted:
Jul 27, 2022
Last Verified:
Jul 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 27, 2022